denufosol inn inhaled drug treatment cystic fibrosis developed inspire pharmaceuticals sponsored cystic fibrosis foundation tested two phase iii clinical trials initially first phase iii trial compound showed significant results compared second phase iii trial compound meet primary endpoint significant change baseline forced expiratory volume one second week endpoint compared additional clinical studies conducted compound drug also investigated treatment retinal detachment retinal diseases trials terminated phase iii studies denufosol orally inhaled patients cystic fibrosis three times day using jet nebulizer effective reach deeper parts lung bronchioles making unsuitable children five years cystic fibrosis characterised defect chloride channel cftr cystic fibrosis transmembrane conductance regulator epithelial cells lungs cftr regulates components sweat digestive juices mucus defects lead viscous dehydrated mucus hindering mucociliary clearance denufosol agonist subtype purinergic receptors via associated g protein leads activation alternative chloride channel activating alternate chloride channel theoretically increases ion transport cystic fibrosis patients compensates effects caused nonfunctioning denufosol consists two nucleosides composed nucleobase sugar deoxycytidine uridine linked sugars four units phosphoric acid used form tetrasodium saltcitation needed httpsenwikipediaorgwikidenufosol